No central action of CGRP antagonising drugs in the GTN mouse model of migraine.
Sarah Louise ChristensenCharlotte ErnstsenJes OlesenDavid M KristensenPublished in: Cephalalgia : an international journal of headache (2020)
The site of action of olcegepant and of the monoclonal antibody ALD405 is outside the blood-brain barrier in this mouse model of migraine. It is likely that these results can be generalised to all gepants and all antibodies and that the results are relevant for human migraine.